Editas Stock Based Compensation from 2010 to 2024

EDIT Stock

USD 2.38 0.06 2.46%

Editas Medicine Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2014-12-31

Previous Quarter

5 M

Current Value

4.8 M

Quarterly Volatility

2.9 M

Yuan Drop

Covid

Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 3 M or Selling General Administrative of 57.9 M, as well as many indicators such as Price To Sales Ratio of 9.36, Dividend Yield of 0.0 or PTB Ratio of 2.31. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.

Check out the analysis of Editas Medicine Correlation against competitors.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Latest Editas Medicine's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Editas Medicine over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Editas Medicine's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Editas Stock Based Compensation Regression Statistics

	Arithmetic Mean	15,658,473
	Geometric Mean	2,905,964
	Coefficient Of Variation	89.34
	Mean Deviation	12,019,045
	Median	19,798,000
	Standard Deviation	13,989,851
	Sample Variance	195.7T
	Range	43.3M
	R-Value	0.81
	Mean Square Error	71T
	R-Squared	0.66
	Significance	0.0002
	Slope	2,547,738
	Total Sum of Squares	2740T

Editas Stock Based Compensation History

	2024	21.3 M
	2023	19.8 M
	2022	29.3 M
	2021	43.4 M
	2020	23.2 M
	2019	27.2 M
	2018	26.6 M

Other Fundumenentals of Editas Medicine

Stock Based Compensation To Revenue

Editas Medicine Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Common Stock	Short Term Investments	Capital Surpluse	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.81	-0.83	0.86	0.75	0.99	0.61	0.95	0.66	0.85	0.38	0.93	0.75	0.85	0.8	0.96	0.92	-0.66	0.78	0.6	0.75	0.65
Total Stockholder Equity	0.95		-0.81	-0.83	0.82	0.51	0.91	0.5	1.0	0.59	0.68	0.39	0.86	0.58	0.82	0.84	0.93	0.93	-0.63	0.87	0.62	0.83	0.72
Net Debt	-0.81	-0.81		0.57	-0.7	-0.52	-0.84	-0.81	-0.8	-0.87	-0.66	-0.09	-0.73	-0.58	-0.52	-0.49	-0.76	-0.68	0.45	-0.53	-0.63	-0.41	-0.34
Retained Earnings	-0.83	-0.83	0.57		-0.87	-0.54	-0.77	-0.36	-0.85	-0.41	-0.67	-0.78	-0.88	-0.6	-0.89	-0.93	-0.8	-0.94	0.9	-0.77	-0.21	-0.85	-0.92
Accounts Payable	0.86	0.82	-0.7	-0.87		0.64	0.82	0.57	0.85	0.61	0.78	0.55	0.86	0.7	0.87	0.82	0.79	0.91	-0.68	0.59	0.23	0.7	0.71
Total Liab	0.75	0.51	-0.52	-0.54	0.64		0.81	0.63	0.52	0.57	0.89	0.24	0.77	0.87	0.61	0.41	0.67	0.55	-0.49	0.31	0.34	0.3	0.27
Total Current Assets	0.99	0.91	-0.84	-0.77	0.82	0.81		0.69	0.9	0.71	0.86	0.29	0.94	0.78	0.78	0.7	0.95	0.85	-0.63	0.7	0.63	0.63	0.54
Property Plant Equipment	0.61	0.5	-0.81	-0.36	0.57	0.63	0.69		0.5	0.86	0.72	-0.02	0.66	0.69	0.38	0.18	0.56	0.41	-0.38	0.09	0.27	0.02	0.05
Net Tangible Assets	0.95	1.0	-0.8	-0.85	0.85	0.52	0.9	0.5		0.59	0.7	0.44	0.87	0.6	0.85	0.87	0.93	0.96	-0.67	0.86	0.57	0.84	0.76
Current Deferred Revenue	0.66	0.59	-0.87	-0.41	0.61	0.57	0.71	0.86	0.59		0.68	0.11	0.62	0.66	0.39	0.26	0.58	0.47	-0.38	0.28	0.4	0.23	0.12
Long Term Debt	0.85	0.68	-0.66	-0.67	0.78	0.89	0.86	0.72	0.7	0.68		0.31	0.82	0.98	0.82	0.57	0.71	0.71	-0.54	0.47	0.31	0.49	0.47
Net Receivables	0.38	0.39	-0.09	-0.78	0.55	0.24	0.29	-0.02	0.44	0.11	0.31		0.54	0.29	0.57	0.69	0.38	0.59	-0.84	0.45	-0.3	0.68	0.8
Deferred Long Term Liab	0.93	0.86	-0.73	-0.88	0.86	0.77	0.94	0.66	0.87	0.62	0.82	0.54		0.73	0.81	0.76	0.94	0.87	-0.83	0.65	0.36	0.66	0.66
Short Long Term Debt	0.75	0.58	-0.58	-0.6	0.7	0.87	0.78	0.69	0.6	0.66	0.98	0.29	0.73		0.77	0.48	0.59	0.61	-0.49	0.4	0.24	0.41	0.41
Short Term Debt	0.85	0.82	-0.52	-0.89	0.87	0.61	0.78	0.38	0.85	0.39	0.82	0.57	0.81	0.77		0.9	0.74	0.92	-0.68	0.75	0.25	0.82	0.85
Common Stock	0.8	0.84	-0.49	-0.93	0.82	0.41	0.7	0.18	0.87	0.26	0.57	0.69	0.76	0.48	0.9		0.76	0.96	-0.75	0.83	0.3	0.92	0.95
Short Term Investments	0.96	0.93	-0.76	-0.8	0.79	0.67	0.95	0.56	0.93	0.58	0.71	0.38	0.94	0.59	0.74	0.76		0.87	-0.7	0.76	0.6	0.71	0.61
Capital Surpluse	0.92	0.93	-0.68	-0.94	0.91	0.55	0.85	0.41	0.96	0.47	0.71	0.59	0.87	0.61	0.92	0.96	0.87		-0.73	0.81	0.4	0.87	0.87
Long Term Debt Total	-0.66	-0.63	0.45	0.9	-0.68	-0.49	-0.63	-0.38	-0.67	-0.38	-0.54	-0.84	-0.83	-0.49	-0.68	-0.75	-0.7	-0.73		-0.59	-0.06	-0.66	-0.78
Net Invested Capital	0.78	0.87	-0.53	-0.77	0.59	0.31	0.7	0.09	0.86	0.28	0.47	0.45	0.65	0.4	0.75	0.83	0.76	0.81	-0.59		0.61	0.93	0.8
Net Working Capital	0.6	0.62	-0.63	-0.21	0.23	0.34	0.63	0.27	0.57	0.4	0.31	-0.3	0.36	0.24	0.25	0.3	0.6	0.4	-0.06	0.61		0.34	0.1
Long Term Investments	0.75	0.83	-0.41	-0.85	0.7	0.3	0.63	0.02	0.84	0.23	0.49	0.68	0.66	0.41	0.82	0.92	0.71	0.87	-0.66	0.93	0.34		0.91
Capital Stock	0.65	0.72	-0.34	-0.92	0.71	0.27	0.54	0.05	0.76	0.12	0.47	0.8	0.66	0.41	0.85	0.95	0.61	0.87	-0.78	0.8	0.1	0.91

Click cells to compare fundamentals

About Editas Medicine Financial Statements

Editas Medicine shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	19.8 M	21.3 M
Stock Based Compensation To Revenue	0.25	0.24

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Editas Stock Based Compensation from 2010 to 2024

Latest Editas Medicine's Stock Based Compensation Growth Pattern

Editas Stock Based Compensation Regression Statistics

Editas Stock Based Compensation History

Other Fundumenentals of Editas Medicine

Editas Medicine Stock Based Compensation component correlations

About Editas Medicine Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Editas Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY